These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9243527)

  • 1. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
    Xu XJ; Elfvin A; Hao JX; Fournié-Zaluski MC; Roques BP; Wiesenfeld-Hallin Z
    Neuropeptides; 1997 Jun; 31(3):287-91. PubMed ID: 9243527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
    Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
    J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
    Coudoré-Civiale MA; Méen M; Fournié-Zaluski MC; Boucher M; Roques BP; Eschalier A
    Br J Pharmacol; 2001 May; 133(1):179-85. PubMed ID: 11325808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
    Valverde O; Blommaert AG; Fournié-Zaluski MC; Roques BP; Maldonado R
    Eur J Pharmacol; 1995 Nov; 286(1):79-93. PubMed ID: 8566154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.
    Wiesenfeld-Hallin Z; Xu XJ; Hughes J; Horwell DC; Hökfelt T
    Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7105-9. PubMed ID: 1698290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased spinal cholecystokinin activity after systemic resiniferatoxin: electrophysiological and in situ hybridization studies.
    Broberger C; Farkas-Szallasi T; Szallasi A; Lundberg JM; Hökfelt T; Wiesenfeld-Hallin Z; Xu XJ
    Pain; 2000 Jan; 84(1):21-28. PubMed ID: 10601669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
    Maldonado R; Valverde O; Ducos B; Blommaert AG; Fournie-Zaluski MC; Roques BP
    Br J Pharmacol; 1995 Mar; 114(5):1031-9. PubMed ID: 7780637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
    Smadja C; Ruiz F; Coric P; Fournié-Zaluski MC; Roques BP; Maldonado R
    Psychopharmacology (Berl); 1997 Aug; 132(3):227-36. PubMed ID: 9292622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the effect of systemic PD134308 (CAM 958) in spinal reflex and pain models with special reference to interaction with morphine and intrathecal galanin.
    Wiesenfeld-Hallin Z; Xu XJ; Hughes J; Horwell DC; Hökfelt T
    Neuropeptides; 1991 Jul; 19 Suppl():79-84. PubMed ID: 1715529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats.
    Xu XJ; Hökfelt T; Hughes J; Wiesenfeld-Hallin Z
    Neuroreport; 1994 Feb; 5(6):718-20. PubMed ID: 8199346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
    Noble F; Blommaert A; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1995 Jan; 273(1-2):145-51. PubMed ID: 7737308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats.
    Coudoré-Civiale MA; Courteix C; Fialip J; Boucher M; Eschalier A
    Pain; 2000 Oct; 88(1):15-22. PubMed ID: 11098095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the role of cholecystokinin in the mediation of spinal reflex excitability in intact and axotomized rats.
    Lucas GA; Xu XJ; Wiesenfeld-Hallin Z
    Neuropeptides; 1998 Feb; 32(1):73-8. PubMed ID: 9571648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential modulation of alpha 2-adrenergic and opioid spinal antinociception by cholecystokinin and cholecystokinin antagonists in the rat dorsal horn: an electrophysiological study.
    Sullivan AF; Hewett K; Dickenson AH
    Brain Res; 1994 Oct; 662(1-2):141-7. PubMed ID: 7859067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins.
    Ruiz-Gayo M; Durieux C; Fournié-Zaluski MC; Roques BP
    J Neurochem; 1992 Nov; 59(5):1805-11. PubMed ID: 1357099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of opioid-induced conditioned place preference by the selective serotonin reuptake inhibitor fluoxetine.
    Subhan F; Pache DM; Sewell RD
    Eur J Pharmacol; 2000 Feb; 390(1-2):137-43. PubMed ID: 10708717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies.
    Xu XJ; Hoffmann O; Wiesenfeld-Hallin Z
    Neuropeptides; 1996 Apr; 30(2):203-6. PubMed ID: 8771563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses.
    Maldonado R; Derrien M; Noble F; Roques BP
    Neuroreport; 1993 Jul; 4(7):947-50. PubMed ID: 8369487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats.
    Hoffmann O; Wiesenfeld-Hallin Z
    Neuroreport; 1994 Dec; 5(18):2565-8. PubMed ID: 7696605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.